glp-1 and gip receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica The Emerging Role of Dual
Description
Despite the promise of these new therapies to address all parts of the CVD/diabetes/obesity triad, approval and broad reimbursement for all these uses are likely still a few years off
Hypoglycemia: This is when blood sugar drops too low, and can happen if youre already taking a medication to control blood sugar
Risks One of the risks that has been discovered with GLP-1 agonists is an increased risk of thyroid cancer, specifically medullary thyroid carcinoma
The onset of cardiovascular disease (CVD) is proposed to be mediated by a multitude of drivers, like metabolic stressors, cardiac and vascular dysfunction, impaired angiogenesis, and the development of atherosclerosis [2]
(Lausanne) 12 , 763646 (2021)
Not immediately
